A Phase 3 interventional study of Vedolizumab SC in Colitis, Ulcerative and Crohn's Disease, sponsored by Takeda. Completed at 301 sites in 33 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-03.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 5th largest by enrollment, is one of 3 that started in 2016, is one of 14 in phase 3, and was the 9th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Australia, Belgium and 15 more countries
Ages 2+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 746 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 110 across the 38 interventional studies. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 38 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
68 studies in Colitis, Ulcerative by Takeda: 6 open now, 10 under way, 5 of them phase 3. Of 54 finished, 35 (65%) have results posted.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 6th largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2016, is one of 21 in phase 3, and was the 20th registered.
Takeda’s Colitis, Ulcerative studies by the year they started, since 2003.
4 of the studies testing vedolizumab in Colitis, Ulcerative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 68 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The main aim of the study is to check for long-term side effects of Vedolizumab Subcutaneous (also known as Vedolizumab SC) in people with ulcerative colitis (UC) and Crohn's disease (CD). Vedolizumab SC will be given as an injection just under the skin. This type of injection is called a subcutaneous injection or SC for short. Another aim of the study is to collect information on whether the participant's condition remains under control or improves during and after treatment with Vedolizumab SC.
Participants who previously took part in studies MLN0002SC-3027 or MLN0002SC-3031 will be invited to visit the study clinic. At this visit, the study doctor will check if each participant can take part in this study.
For those who can take part, participants will receive a subcutaneous injection of vedolizumab SC either once a week or once every 2 weeks. How often each participant receives vedolizumab SC will depend on their results from the previous study and on how active their condition is. Participants might be able to self-inject vedolizumab SC after being trained by the study doctors. During this study, the dose of vedolizumab SC might be increased for participants whose condition worsens.
Participants will continue treatment with vedolizumab SC until it is approved in their particular country, the participant decides to stop treatment, or the sponsor stops the study. If the sponsor stops the study before vedolizumab SC is approved in all countries, the sponsor will make sure all affected participants will have access to vedolizumab SC outside of the study.
After their final dose of vedolizumab SC, participants will visit the clinic 18 weeks later for a final check-up. Then, the clinic will telephone the participants 6 months after their final dose of vedolizumab SC to check if they have any health problems.
The drug being tested in this study is called vedolizumab subcutaneous (vedolizumab SC). Vedolizumab SC is being tested to assess its long-term safety and effectiveness in treating participants with UC or CD. This study will look at the long-term side effects and response/remission of UC and CD in participants who received vedolizumab SC in a prior vedolizumab SC study.
The study will enroll up to 692 patients. All participants enrolled in this study will have previously participated in the MLN0002SC-3027 or MLN0002SC-3031 study. Participants who completed the Maintenance Period (Week 52) in their previous study, or who did not achieve a clinical response at Week 6 but who did achieve a clinical response at Week 14 after having received a third vedolizumab IV infusion at Week 6 in their previous study, will receive open-label vedolizumab SC 108 mg, once every 2 weeks (Q2W). Participants who withdrew early from the Maintenance Period of their previous study due to disease worsening or need for rescue medications will receive open-label vedolizumab SC 108 mg, once every week (QW). Participants receiving SC 108 mg Q2W who experience treatment failure (disease worsening or need for rescue medications while in the current study will be dose escalated to vedolizumab SC 108 mg QW.
This multi-center trial will be conducted worldwide. Participation in this vedolizumab SC study will continue until vedolizumab SC becomes commercially available, the participant withdraws from the study, or the sponsor decides to close the study. Participants will make multiple visits to the clinic, plus a final visit 18 weeks after last dose of study drug for a follow-up assessment. Participants will also participate in a long-term safety follow-up, by phone, at 6 months after the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with ulcerative colitis (UC) who completed the Maintenance Phase in MLN0002SC-3027 (Week 52 assessment) or who did not achieve a clinical response at Week 6 in MLN0002SC-3027 but who did achieve a clinical response at Week 14 of the parent study after having received a third vedolizumab IV infusion at Week 6 in the parent study received vedolizumab SC 108 mg Q2W in this study whereas who withdrew early from the Maintenance Phase (at Week 14 onwards) in MLN0002SC-3027 due to disease worsening or need for rescue medications received vedolizumab SC 108 mg QW.
Drug: Vedolizumab SC
Participants with Crohn's disease (CD) who completed the Maintenance Phase in MLN0002SC-3031 (Week 52 assessment) or who did not achieve a clinical response at Week 6 in MLN0002SC-3031 but who did achieve a clinical response at Week 14 of the parent study after having received a third vedolizumab IV infusion at Week 6 in the parent study received vedolizumab SC 108 mg Q2W in this study whereas who withdrew early from the Maintenance Phase (at Week 14 onwards) in MLN0002SC-3031 due to disease worsening or need for rescue medications received vedolizumab SC 108 mg QW.
Drug: Vedolizumab SC
Vedolizumab SC 108 mg injection
Number of Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment
A TEAE was defined as an adverse event (AE) that started or worsened on or after study Day 1 (defined as day first dosed) and no more than 18 weeks after the last dose of study drug. An SAE was defined as any untoward medical occurrence that occurs at any dose and resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was an important medical event such as acute liver failure, pulmonary hypertension, or confirmed or suspected transmission of an infectious agent by a medicinal product. Participant years is defined as the total exposure-time of the participants in the respective treatment group. Incidence per 100 participant years is defined as (Number of participants with events\*100/participant years). As per planned analysis, data for this outcome measure is grouped and presented per disease condition.
Time frame: Up to 97.9 months
Number of Adverse Events of Special Interest (AESIs) Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment
AESIs included hypersensitivity reactions (including injections site reactions), serious infections, malignancies, hepatotoxicity (abnormal liver function test) and progressive multifocal leukoencephalopathy (PML). Participant years is defined as the total exposure-time of the participants in the respective treatment group. Incidence per 100 participant years is defined as (Number of participants with events\*100/participant years). As per planned analysis, data for this outcome measure is grouped and presented per disease condition.
Time frame: Up to 97.9 months
Number of Participants With Ulcerative Colitis Achieving Partial Mayo Scoring Clinical Response at Week 48
Clinical response is defined as a decrease in the partial Mayo score of at least 2 points and ≥25% from baseline, with an accompanying decrease in rectal bleeding subscore of ≥1 point from baseline or absolute rectal bleeding subscore of ≤1 point. As per planned analysis, data for this outcome measure is grouped and presented for participants with ulcerative colitis.
Time frame: Week 48
Number of Participants With Crohn's Disease Achieving Clinical Response Based on Harvey-Bradshaw Index (HBI) Scores at Week 48
Clinical response is defined as a decrease in HBI score of ≥3 points from baseline in CD participants (randomized early terminator CD participants only \[defined as randomized CD participants withdrawn from the parent study between Week 6 and Week 52\]). As per planned analysis, data for this outcome measure is grouped and presented for participants with Crohn's disease.
Time frame: Week 48
Number of Participants With Ulcerative Colitis Achieving Clinical Remission Based on Partial Mayo Score
Clinical remission is defined as a partial Mayo score of ≤2 with no individual subscore \>1. As per planned analysis, data for this outcome measure is grouped and presented for participants with ulcerative colitis.
Time frame: Week 48
Number of Participants With Crohn's Disease Achieving Clinical Remission Based on Harvey-Bradshaw Index (HBI) Scores
Clinical remission is defined as total HBI score of ≤4 points. As per planned analysis, data for this outcome measure is grouped and presented for participants with Crohn's disease.
Time frame: Week 48
Participants took part in the study at various investigative sites globally from 15 April 2016 to 12 June 2024.
| Milestone | Ulcerative Colitis: Vedolizumab 108 mg | Crohn's Disease: Vedolizumab 108 mg |
|---|---|---|
| Started | 288 | 458 |
| Completed | 125 | 162 |
| Not completed | 163 | 296 |
| Withdrew: Adverse event | 22 | 42 |
| Withdrew: Lost to follow-up | 4 | 10 |
| Withdrew: Withdrawal by subject | 36 | 66 |
| Withdrew: Site termination | 3 | 3 |
| Withdrew: Pregnancy | 3 | 7 |
| Withdrew: Lack of efficacy | 81 | 146 |
| Withdrew: Leukopenia or lymphopenia | 1 | 0 |
| Withdrew: Reason not specified | 13 | 21 |
| Withdrew: Significant protocol deviation | 0 | 1 |
A TEAE was defined as an adverse event (AE) that started or worsened on or after study Day 1 (defined as day first dosed) and no more than 18 weeks after the last dose of study drug. An SAE was defined as any untoward medical occurrence that occurs at any dose and resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was an important medical event such as acute liver failure, pulmonary hypertension, or confirmed or suspected transmission of an infectious agent by a medicinal product. Participant years is defined as the total exposure-time of the participants in the respective treatment group. Incidence per 100 participant years is defined as (Number of participants with events\*100/participant years). As per planned analysis, data for this outcome measure is grouped and presented per disease condition.
| events per 100 participant years | Ulcerative Colitis: Vedolizumab 108 mg | Crohn's Disease: Vedolizumab 108 mg |
|---|---|---|
| TEAEs | 22.9 | 28.0 |
| Serious TEAEs | 6.5 | 8.7 |
AESIs included hypersensitivity reactions (including injections site reactions), serious infections, malignancies, hepatotoxicity (abnormal liver function test) and progressive multifocal leukoencephalopathy (PML). Participant years is defined as the total exposure-time of the participants in the respective treatment group. Incidence per 100 participant years is defined as (Number of participants with events\*100/participant years). As per planned analysis, data for this outcome measure is grouped and presented per disease condition.
| events per 100 participant years | Ulcerative Colitis: Vedolizumab 108 mg | Crohn's Disease: Vedolizumab 108 mg |
|---|---|---|
| Number of Adverse Events of Special Interest (AESIs) Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment | 16.3 | 17.4 |
Clinical response is defined as a decrease in the partial Mayo score of at least 2 points and ≥25% from baseline, with an accompanying decrease in rectal bleeding subscore of ≥1 point from baseline or absolute rectal bleeding subscore of ≤1 point. As per planned analysis, data for this outcome measure is grouped and presented for participants with ulcerative colitis.
| Participants | Ulcerative Colitis: Vedolizumab 108 mg |
|---|---|
| Number of Participants With Ulcerative Colitis Achieving Partial Mayo Scoring Clinical Response at Week 48 | 168 |
Clinical response is defined as a decrease in HBI score of ≥3 points from baseline in CD participants (randomized early terminator CD participants only \[defined as randomized CD participants withdrawn from the parent study between Week 6 and Week 52\]). As per planned analysis, data for this outcome measure is grouped and presented for participants with Crohn's disease.
| Participants | Crohn's Disease: Vedolizumab 108 mg |
|---|---|
| Number of Participants With Crohn's Disease Achieving Clinical Response Based on Harvey-Bradshaw Index (HBI) Scores at Week 48 | 32 |
Clinical remission is defined as a partial Mayo score of ≤2 with no individual subscore \>1. As per planned analysis, data for this outcome measure is grouped and presented for participants with ulcerative colitis.
| Participants | Ulcerative Colitis: Vedolizumab 108 mg |
|---|---|
| Number of Participants With Ulcerative Colitis Achieving Clinical Remission Based on Partial Mayo Score | 150 |
Clinical remission is defined as total HBI score of ≤4 points. As per planned analysis, data for this outcome measure is grouped and presented for participants with Crohn's disease.
| Participants | Crohn's Disease: Vedolizumab 108 mg |
|---|---|
| Number of Participants With Crohn's Disease Achieving Clinical Remission Based on Harvey-Bradshaw Index (HBI) Scores | 217 |
Collected over Up to 97.9 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ulcerative Colitis: Only Vedolizumab Q2W | 3/163 (1.8%) | 29/163 (17.8%) | 94/163 (57.7%) |
| Ulcerative Colitis: Only Vedolizumab QW | 0/60 (0%) | 12/60 (20%) | 41/60 (68.3%) |
| Ulcerative Colitis: Vedolizumab Dose Escalation From Q2W to QW | 0/65 (0%) | 24/65 (36.9%) | 55/65 (84.6%) |
| Crohn's Disease: Only Vedolizumab Q2W | 2/239 (0.8%) | 55/239 (23%) | 151/239 (63.2%) |
| Crohn's Disease: Only Vedolizumab QW | 0/117 (0%) | 35/117 (29.9%) | 78/117 (66.7%) |
| Crohn's Disease: Vedolizumab Dose Escalation From Q2W to QW | 0/102 (0%) | 31/102 (30.4%) | 90/102 (88.2%) |
| Event | Ulcerative Colitis: Only Vedolizumab Q2W | Ulcerative Colitis: Only Vedolizumab QW | Ulcerative Colitis: Vedolizumab Dose Escalation From Q2W to QW | Crohn's Disease: Only Vedolizumab Q2W | Crohn's Disease: Only Vedolizumab QW | Crohn's Disease: Vedolizumab Dose Escalation From Q2W to QW |
|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 4/163 | 7/60 | 11/65 | 0/239 | 0/117 | 0/102 |
| Crohn's diseaseGastrointestinal disorders | 0/163 | 0/60 | 0/65 | 4/239 | 10/117 | 14/102 |
| AnaemiaBlood and lymphatic system disorders | 3/163 | 1/60 | 6/65 | 3/239 | 3/117 | 0/102 |
| Acute kidney injuryRenal and urinary disorders | 0/163 | 0/60 | 2/65 | 1/239 | 0/117 | 0/102 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/163 | 0/60 | 2/65 | 0/239 | 0/117 | 0/102 |
| PneumoniaInfections and infestations | 0/163 | 0/60 | 0/65 | 1/239 | 1/117 | 3/102 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/61 | 0/27 | 0/32 | 0/106 | 0/63 | 1/45 |
| Small intestinal obstructionGastrointestinal disorders | 0/163 | 0/60 | 0/65 | 5/239 | 1/117 | 1/102 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/163 | 0/60 | 1/65 | 0/239 | 2/117 | 0/102 |
| DiarrhoeaGastrointestinal disorders | 0/163 | 0/60 | 0/65 | 0/239 | 2/117 | 0/102 |
| Event | Ulcerative Colitis: Only Vedolizumab Q2W | Ulcerative Colitis: Only Vedolizumab QW | Ulcerative Colitis: Vedolizumab Dose Escalation From Q2W to QW | Crohn's Disease: Only Vedolizumab Q2W | Crohn's Disease: Only Vedolizumab QW | Crohn's Disease: Vedolizumab Dose Escalation From Q2W to QW |
|---|---|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 1/163 | 0/60 | 0/65 | 26/239 | 30/117 | 53/102 |
| Colitis ulcerativeGastrointestinal disorders | 8/163 | 14/60 | 33/65 | 0/239 | 0/117 | 0/102 |
| NasopharyngitisInfections and infestations | 23/163 | 11/60 | 15/65 | 26/239 | 16/117 | 20/102 |
| Upper respiratory tract infectionInfections and infestations | 28/163 | 6/60 | 7/65 | 38/239 | 13/117 | 18/102 |
| Abdominal painGastrointestinal disorders | 8/163 | 3/60 | 2/65 | 33/239 | 20/117 | 15/102 |
| COVID-19Infections and infestations | 24/163 | 2/60 | 5/65 | 29/239 | 4/117 | 9/102 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/163 | 3/60 | 5/65 | 34/239 | 14/117 | 11/102 |
| AnaemiaBlood and lymphatic system disorders | 3/163 | 5/60 | 9/65 | 14/239 | 3/117 | 6/102 |
| HeadacheNervous system disorders | 8/163 | 3/60 | 7/65 | 19/239 | 5/117 | 14/102 |
| NauseaGastrointestinal disorders | 7/163 | 1/60 | 3/65 | 14/239 | 7/117 | 13/102 |
The Safety Analysis Set (SAF) included all participants who had received at least 1 dose of study medication in this study (MLN0002SC-3030). As per planned analysis, baseline characteristics data was collected and presented per disease condition in the arm groups, 'Ulcerative Colitis: Vedolizumab 108 mg' and 'Crohn's Disease: Vedolizumab 108 mg'.
| Age, Categorical(Participants) | Ulcerative Colitis: Vedolizumab 108 mg | Crohn's Disease: Vedolizumab 108 mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 265 | 440 | 705 |
| >=65 years | 23 | 18 | 41 |
| Sex: Female, Male(Participants) | Ulcerative Colitis: Vedolizumab 108 mg | Crohn's Disease: Vedolizumab 108 mg | Total |
|---|---|---|---|
| Female | 120 | 214 | 334 |
| Male | 168 | 244 | 412 |
| Ethnicity (NIH/OMB)(Participants) | Ulcerative Colitis: Vedolizumab 108 mg | Crohn's Disease: Vedolizumab 108 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 4 |
| Not Hispanic or Latino | 34 | 94 | 128 |
| Unknown or Not Reported | 253 | 361 | 614 |
| Race (NIH/OMB)(Participants) | Ulcerative Colitis: Vedolizumab 108 mg | Crohn's Disease: Vedolizumab 108 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 4 |
| Asian | 58 | 28 | 86 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 2 | 9 | 11 |
| White | 226 | 417 | 643 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
Showing the first 100 of 301 sites across 33 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2016 to primary completion in Jun 2024, 97 months.
Results were first posted in Apr 2025, 9 months after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 97 months is above that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab